Please ensure Javascript is enabled for purposes of website accessibility

CVS Looks Healthy

By Nate Parmelee – Updated Nov 15, 2016 at 7:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugstore chain handles acquisitions without indigestion.

I'm rarely impressed by a company that has recently swallowed a relatively large acquisition and is signing up for another. But I can't complain about the fourth-quarter and fiscal 2005 results that CVS (NYSE:CVS) reported Thursday morning.

The company is doing extremely well more than a year and a half after gobbling up Eckerd's. Given that successful addition, I'm beginning to think that an accretive addition to 2007 earnings and cash flow might not be the only thing to like about the company's acquisition of Osco and Sav-On stores from Albertson's (NYSE:ABS). The deal also increases the company's exposure in markets where it currently lacks a large presence. If the buyout is as successful as the Eckerd's acquisition, it may also mean gradually more efficient and profitable stores.

Of course, it doesn't hurt that sales, earnings per share, and free cash flow were all up for the year. Sales rose 21%, earnings per diluted share were up 25.5% (after removing a one-time benefit of $0.07), and free cash flow was up to $656.6 million after last year's dip to $63.1 million. In calculating the free cash flow, I've excluded the acquisition of Eckerd's, and I've given the company credit for its sale-leaseback proceeds. However, if the company continues to make smaller acquisitions like the Albertson's deal, I think a reasonable case can be made to start looking at numbers with acquisitions included.

Earnings and free cash flow were impressive at CVS this quarter, but I'm more impressed with the company's balance sheet; across the board, the company seems in better shape than it was a year ago. Working capital growth was tame compared to sales growth for the year, short-term debt was reduced by 71%, long-term debt is down, and none of the "other" accounts is so drastically out of line that it warrants a discussion.

While Walgreen (NYSE:WAG) is generally considered the top of the class in the drugstore industry, I think that CVS is compelling enough to deserve consideration. I've often thought that both CVS and Walgreen need to be concerned with the inroads that Costco Wholesale (NASDAQ:COST) and Wal-Mart Stores (NYSE:WMT) have made into the drugstore space, but the much smaller footprint of traditional CVS and Walgreen's stores allows them access to urban locations that are more convenient for some consumers. In short, I don't see why there isn't room for all of them, so long as each sticks to territory where it has a relative advantage.

Further doses of over-the-counter Foolishness:

Costco Wholesale is a Motley Fool Stock Advisor recommendation. Want David and Tom Gardner's prescription for a healthy portfolio? Sign up today for a 30-day free trial.

Nathan Parmelee owns shares in Costco, but has no financial stake in any of the other companies mentioned. The Motley Fool has an ironclad disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walmart Stock Quote
Walmart
WMT
$131.31 (0.96%) $1.25
Costco Wholesale Corporation Stock Quote
Costco Wholesale Corporation
COST
$480.30 (2.98%) $13.90
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$97.74 (-0.62%) $0.61
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.69 (-0.43%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.